Novo Nordisk A/S $NVO Position Increased by Diamant Asset Management Inc.

Diamant Asset Management Inc. lifted its position in Novo Nordisk A/S (NYSE:NVO) by 2,030.1% during the 1st quarter, HoldingsChannel.com reports. The fund owned 401,310 shares of the company’s stock after buying an additional 382,470 shares during the quarter. Diamant Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $14,748,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Godfrey Financial Associates Inc. purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $25,000. WealthCollab LLC grew its position in Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares in the last quarter. American National Bank & Trust acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at $28,000. Maseco LLP acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at $29,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at $29,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the subject of several recent analyst reports. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price on the stock in a research note on Tuesday, March 3rd. Finally, Sanford C. Bernstein initiated coverage on shares of Novo Nordisk A/S in a research report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Trading Up 0.8%

Novo Nordisk A/S stock opened at $48.01 on Friday. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $71.79. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The stock has a market cap of $214.36 billion, a P/E ratio of 11.27, a P/E/G ratio of 4.30 and a beta of 0.78. The company’s fifty day simple moving average is $43.79 and its 200-day simple moving average is $45.83.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.42 EPS for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.